| SARS-CoV-2 E protein | is | conserved (count: 1) | |
|---|---|
| This result shows SARS-CoV-2 E protein is conserved only in SARS clade and E from MERS or other animal coronaviruses clusters in different clusters (see Figure 2 ).
| |
| three amino acid substitutions | is in | E protein of SARS-CoV-2 (count: 1) | |
| MSA results illustrate ( Figure 4E ) that this protein is highly conserved, with only three amino acid substitutions in E protein of SARS-CoV-2 conferring its 96% sequence similarity with Human SARS and Bat CoV. Bat CoV shares 100% sequence identity with Human SARS.
-- Dark proteome of Newly Emerged SARS-CoV-2 in Comparison with Human and Bat Coronaviruses. biorxiv. 2020-03-14. | |
| graphs | indicates | disorder in E proteins of SARS-CoV-2 (count: 1) | |
| Respective graphs in figure 4A , 4B, and 4C indicates the predicted intrinsic disorder in E proteins of SARS-CoV-2, Human SARS, and Bat CoV.
-- Dark proteome of Newly Emerged SARS-CoV-2 in Comparison with Human and Bat Coronaviruses. biorxiv. 2020-03-14. | |
| We | investigated | similarity of E protein of 2019-nCoV (count: 1) | |
| We investigated the similarity of the E protein of 2019-nCoV by phylogenetic analysis against known coronavirus E protein sequences ( Figure 6 ) and found clustering, although somewhat distant, with human SARS-CoV. Given that vaccines have been generated for MERSand SARS-CoVs by mutating the E protein, an E-based vaccine may represent an alternate candidate for 2019-nCoV vaccines.
-- 2019-nCoV (Wuhan virus), a novel Coronavirus: Human-to-human transmission, travel-related cases, and vaccine readiness. Journal of Infection in Developing Countries. 2020. | |